ABSTRACT
Chemotherapy has been a standard treatment for women with a high risk of breast cancer recurrence for decades. As each new chemotherapy regimen has been trialled, incremental benefits have been demonstrated, initially between CMF (cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy and placebo, and more recently when compared to the previous standard chemotherapy. Numerous clinical trials have been conducted over several decades, each with slightly different criteria. This research involved collection and meta-analysis of individual patient data from all of the primary trials of adjuvant chemotherapy, giving a unique and powerful insight into the efficacy of different regimens and the subgroups where effects are more notable.
